ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 0049 • ACR Convergence 2021

    CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis

    Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
  • Abstract Number: 1011 • ACR Convergence 2021

    Validation of Bioinformatics Pipeline to Detect NEMO-Deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) and Preliminary Clinical and Immunologic Characterization

    Adriana Almeida de Jesus1, Bin Lin2, Eric Karlins3, Dana Kahle4, Andre Rastegar2, Jacob Mitchell2, Sofia Torreggiani2, Farzana Bhuyan2, Sara Alehashemi5, Kader Cetin Gedik6, Kat Uss2, Chyi-Chia Lee7, Hyesun Kuehn8, Sergio Rosenzweig8, Katherine Calvo8, Magdalena Walkiewicz9, Justin Lack10, Eric Hanson11, Amer Khojah12, Eveline Wu13, Christiaan Scott14, Timothy Ronan Leahy15, Emma MacDermott15, Orla Kileen15, Thaschawee Arkachaisri16, Zoran Gucev17, Kathryn Cook18, Vafa Mammadova19, Gulnara Nasrullayeva19, Scott Canna20, Douglas Kuhns21, Clifton Dalgard22, Timothy Moran23, Andrew Oler3 and Raphaela Goldbach-Mansky24, 1TADS/NIAID/NIH, Silver Spring, MD, 2TADS/NIAID/NIH, Bethesda, MD, 3BCBB/NIAID/NIH, Bethesda, MD, 4National Institutes of Health, Chevy Chase, MD, 5TADS/NIAID/NIH, Clarksville, MD, 6Translational Autoinflammatory Diseases Section (TADS)/NIAID/NIH, Bethesda, MD, 7NCI/NIH, Bethesda, MD, 8CC/DLM/NIH, Bethesda, MD, 9CSI/NIAID/NIH, Bethesda, MD, 10NCBR/NIAID/NIH, Bethesda, MD, 11Indiana University School of Medicine, Indianapolis, IN, 12Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 13UNC Chapel Hill, Chapel Hill, NC, 14Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, 15Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, 16KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, 17University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, 18Akron Childrens Hospital, Copley, OH, 19Azerbaijan Medical University, Baku, Azerbaijan, 20Children's Hospital of Philadelphia, Philadelphia, PA, 21Frederick National Laboratory for Cancer Research/NIH, Frederick, MD, 22TAGC/USUHS, Bethesda, MD, 23University of North Carolina School of Medicine, Chapel Hill, NC, 24NIH/NIAID, Potomac, MD

    Background/Purpose: Splice site variants in IKBKG that lead to exon 5 deletion cause NEMO-deleted exon 5 autoinflammatory syndrome (NEMO-NDAS). NEMO-NDAS clinically mimics the interferonopathy chronic…
  • Abstract Number: 1905 • ACR Convergence 2021

    CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE

    Jennifer Barnas1, Jennifer Barnard2, Cameron Baker2, Nida Meednu2, Andrew McDavid1, R. John Looney1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…
  • Abstract Number: 0050 • ACR Convergence 2021

    Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis

    Maricela Haghiac1, Maya Breitman2, Ricky Chan3, Ahmad Khalil3 and Marina Magrey4, 1Metrohealth Medical center, Cleveland, OH, 2MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, 3Case Western Reserve University, Cleveland, OH, 4Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH

    Background/Purpose: Gender has been shown to impact disease expression in ankylosing spondylitis. Men with AS are more likely to develop radiographic joint damage, while women…
  • Abstract Number: 1012 • ACR Convergence 2021

    Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis

    Serena Foo1, Achilleas Floudas2, Aisling O' Brien1, Sharon Ansboro1, Ronan Mullan3, Douglas Veale4, Emma MacDermott5, Derek Deely6, Charlene Foley6, Orla Killeen6 and Ursula Fearon1, 1Trinity College Dublin, Dublin, Ireland, 2Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, 3Tallaght University Hospital, Dublin, Ireland, 4University College Dublin, Dublin, Ireland, 5Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, 6Children's Health Ireland, Crumlin, Dublin, Ireland

    Background/Purpose: Juvenile idiopathic arthritis (JIA) was thought to be the most common inflammatory arthritis in children. However an aggressive, erosive arthritis of little-known immunologic mechanism…
  • Abstract Number: 0197 • ACR Convergence 2021

    Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series

    Hildrun Haibel1, Stefan Angermair2, Michael Schumann2, Janis Vahldiek3, Denis Poddubnyy4 and Thomas Schneider2, 1Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Charité University Medicine Berlin Campus Benjamin Franklin, Berlin, Germany, 3Charité University Medicine Berlin, Berlin, Germany, 4Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating…
  • Abstract Number: 1105 • ACR Convergence 2021

    Discovering Variants in Suspected Monogenic Systemic Inflammatory Disease: An Adult Case Series

    Jason An1, Madeline Couse1, Dilan Dissanayake2, Daniela Dominguez2, Ronald Laxer1, Christian Marshall1, Johannes Roth3, Robert Rottapel4 and Linda Hiraki2, 1SickKids, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4St Michael's Hospital, Toronto, ON, Canada

    Background/Purpose: Monogenic systemic inflammatory diseases (MSID) are a heterogeneous group of rare conditions caused by single gene variants leading to immune dysregulation. Diagnostic yield of…
  • Abstract Number: 0489 • ACR Convergence 2021

    CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases

    Kofi Mensah1, Rajula Gaur1, Jamie Connarn1, Michael Thomas1, Liangang Liu1, Stuart Mair2, Francisco Ramírez-Valle1 and Maria Palmisano1, 1Bristol Myers Squibb, Princeton, NJ, 2Quotient Sciences, Nottingham, United Kingdom

    Background/Purpose: Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines,…
  • Abstract Number: 1386 • ACR Convergence 2021

    Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH

    Shusaku Nakashima1, Kaori Ishikawa1, Kiyo Ueeda1, Tomohiro Kameda1, Hiromi Shimada1, Risa Wakiya1, Mansour mai1, Mikiya Kato1, Taichi Miyagi2, Koichi Sugihara1, Rina Semba1, Mao Mizusaki1 and Hiroaki Dobashi3, 1Kagawa University, Takamatsu, Japan, 2Kagawa University, Kidagun, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
  • Abstract Number: 0508 • ACR Convergence 2021

    The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation

    Nozima Aripova, Michael Duryee, Evan Ryan, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: In rheumatoid arthritis (RA), chronic synovial inflammation is accompanied by fibrotic responses that together lead to pannus formation and progressive joint damage. Exposure to…
  • Abstract Number: 1423 • ACR Convergence 2021

    Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index

    Melissa Munroe1, Rufei Lu2, Timothy Gross1, George Tsokos3, Michael Keith4, John Harley5 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, 3BIDMC, Boston, MA, 4Inova, Arlington, VA, 5US Department of Veterans Affairs Medical Center, Cincinnati, OH

    Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
  • Abstract Number: 0510 • ACR Convergence 2021

    Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes

    Brittany Wordekemper, Nozima Aripova, Michael Duryee, Eric Daubach, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Malondialdehyde (MDA) is produced in response to oxidative stress and is associated with inflammation and disease pathogenesis. MDA can break down and form acetaldehyde…
  • Abstract Number: 1429 • ACR Convergence 2021

    ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases

    Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA

    Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
  • Abstract Number: 0511 • ACR Convergence 2021

    Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B

    Jorge Romo-Tena1, Jose Esparza-Lopez2, Carmelo Carmona-Rivera3, Luz P blanco3, Mariana Kaplan4 and María de Jesús Ibarra-Sánchez2, 1INNSZ / NIAMS, Mexico City, Mexico, 2INNSZ, Mexico City, Mexico, 3NIAMS, Bethesda, MD, 4National Institutes of Health, Bethesda, MD

    Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
  • Abstract Number: 1438 • ACR Convergence 2021

    Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions

    Renan Vergara1, Alex Chen1, Jerry Chen1, Marianne Riley1, Luis Blancas-Mejia1, Christie Mortales1, Tania Berrocal1, Tanu Priya1, Marsha Mason1, Kevin Yu1, Olga Sharapova1, Jorgen Nelson1, Alfredo Quijano-Rubio1, Thomas Linsky1, Ryan Swanson1 and Daniel-Adriano Silva2, 1Neoleukin Therapeutics, Inc., Seattle, WA, 2Formerly of Neoleukin Therapeutics, Inc., Seattle, WA

    Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology